James Merselis - Trinity Bio Non-Executive Independent Director

TRIB
 Stock
  

USD 1.23  0.08  6.11%   

  Director
James D. Merselis is a Nonexecutive director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. James joined the board of Trinity Biotech in February 2009 as a nonexecutive director. He is currently CEO of Biosensia Ltd a pointofcare diagnostics company located in Dublin, Ireland and is on the boards of Abram Scientific Inc. located in Mountain View, CA, and Cardiac Designs Inc. located in Austin, TX. Mr. Merselis has more than thirtyseven years experience in healthcare, with the first twentytwo years at Boehringer Mannheim Diagnostics
  Director Since 2009      
353 1 276 9800  https://www.trinitybiotech.com
Merselis has led a number of healthcare diagnostic startups. From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a pointofcare diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin. During this time he successfully took the company public followed two years later by its acquisition by Alere . His leadership at other startups has included: Nexus Dx, Alverix, Inc., and Micronics, Inc. .

Trinity Bio Management Efficiency

Trinity Bio ADR has return on total asset (ROA) of 4.57 % which means that it generated profit of $4.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (190.56) %, meaning that it created substantial loss on money invested by shareholders. Trinity Bio management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 97.18 M in liabilities. Trinity Bio ADR has a current ratio of 0.71, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Trinity Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Trinity Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Trinity Bio ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Trinity to invest in growth at high rates of return. When we think about Trinity Bio's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Ellen HoffingPerrigo Company
2008
Joseph EchevarriaPfizer Inc
2015
Shikha SharmaDr Reddys Laboratories
2019
Pinkston PeggySeagen Inc
N/A
Srinivas AkkarajuSeagen Inc
2003
Daniel WelchSeagen Inc
2007
William YoungVertex Pharmaceutic
2014
David GreenwayVertex Pharmaceutic
2017
Nancy SimonianSeagen Inc
2012
Frank DAmelioZoetis Inc Cl
2016
J MoreauDr Reddys Laboratories
2007
Fei WangOrigin Agritech
2019
Arthur RyanRegeneron Pharmaceuticals
2003
Omkar GoswamiDr Reddys Laboratories
2000
Katherine DoylePerrigo Company
2020
Anupam PuriDr Reddys Laboratories
2002
David AltshulerVertex Pharmaceutic
2015
Geoffrey ParkerPerrigo Company
2016
Yingqi XiaOrigin Agritech
2010
Gary CohenPerrigo Company
2009
James QuinceyPfizer Inc
2020
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the United States, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. Trinity Bio ADR (TRIB) is traded on NASDAQ Exchange in USA and employs 543 people.

Trinity Bio ADR Leadership Team

Elected by the shareholders, the Trinity Bio's board of directors comprises two types of representatives: Trinity Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Trinity. The board's role is to monitor Trinity Bio's management team and ensure that shareholders' interests are well served. Trinity Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Trinity Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Coyne, Non-Executive Independent Director
Ronan OCaoimh, Executive Chairman of the Board
Denis Burger, Senior Non-Executive Independent Director
James Merselis, Non-Executive Independent Director
Clinton Severson, Non-Executive Director
Rory Nealon, Chief Operations Officer, Director and Member of Compensation Committee
James Walsh, Executive Director and Member of Compensation Committee
Eric Brouwer, Chief Scientific Officer and VP Cardiac
Kevin Tansley, CFO and Secretary

Trinity Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Trinity Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Trinity Bio Investors Sentiment

The influence of Trinity Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Trinity. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Trinity Bio Implied Volatility

    
  0.0  
Trinity Bio's implied volatility exposes the market's sentiment of Trinity Bio ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Trinity Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Trinity Bio stock will not fluctuate a lot when Trinity Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Trinity Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Trinity Bio's short interest history, or implied volatility extrapolated from Trinity Bio options trading.

Current Sentiment - TRIB

Trinity Bio ADR Investor Sentiment

Most of Macroaxis users are at this time bullish on Trinity Bio ADR. What is your outlook on investing in Trinity Bio ADR? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Additionally, take a look at World Market Map. Note that the Trinity Bio ADR information on this page should be used as a complementary analysis to other Trinity Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Trinity Stock analysis

When running Trinity Bio ADR price analysis, check to measure Trinity Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Bio is operating at the current time. Most of Trinity Bio's value examination focuses on studying past and present price action to predict the probability of Trinity Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Trinity Bio's price. Additionally, you may evaluate how the addition of Trinity Bio to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is Trinity Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Bio. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.77
Market Capitalization
51.1 M
Quarterly Revenue Growth YOY
-0.31
Return On Assets
0.0446
Return On Equity
-1.91
The market value of Trinity Bio ADR is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Bio's value that differs from its market value or its book value, called intrinsic value, which is Trinity Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Bio's market value can be influenced by many factors that don't directly affect Trinity Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Trinity Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.